|
|
Neoprobe
Summary
Neopobe is dedicated to improving the diagnosis and treatment of cancer by the innovative use of intraoperative lymphatic mapping ("ILM") technology. ILM is a minimally invasive technique for evaluating the potential spread of cancer to lymph nodes. Surgeons are using lymphatic mapping as a standard of care for patients with malignant melanoma and investigating its use with breast cancer.
|
These are the most recent reports
|
Neoprobe All reports
|
|
Colors:
Reports
|
Commentary
|
Press Release
|
Pay Per View
|
Neoprobe Corp.
: NEOP: Quantix/ND Neurosurgery Clinical Results Published and Presented; New Technology Permits Bedside Assessment of Blood Flow
September 14, 2003
Neoprobe Corp.
: Neoprobe Receives Marketing Clearance for Quantix/OR in United States; Quantix/OR To Be Delivered to Clinical Sites
September 08, 2003
Neoprobe Corp.
: Neoprobe Launches Second Blood Flow Measurement Product
April 28, 2003
Neoprobe Corp.
: Neoprobe Completes Secured Note Financing
April 07, 2003
Neoprobe Corp.
: Neoprobe Issued Cardiosonix Patent
January 16, 2003
Neoprobe Corp.
: Neoprobe Launches First Cardiosonix Product
November 21, 2002
 Neoprobe Corp.
: 3Q02 Update
November 18, 2002
Neoprobe Corp.
: Neoprobe Provides Cardiosonix Business Update; Quantix/ND On Target
October 02, 2002
Neoprobe Corp.
: Cost Cutting Offsets Sales Decline
August 16, 2002
Neoprobe Corp.
: Neoprobe Announces Second Quarter Results
August 01, 2002
Neoprobe Corp.
: Neoprobe Announces Lymphoseek Clinical Results
June 18, 2002
Neoprobe Corp.
: Neoprobe Announces Neurosurgery Clinical Results
June 17, 2002
Neoprobe Corp.
: 1Q02 Better than Expected Results, On Track to Meet Objectives
June 10, 2002
Neoprobe Corp.
: Neopobe Announces First Distribution Agreement for Cardiosonix Products
June 01, 2002
Neoprobe Corp.
: NEOP'S CEO Interviewed by CEOcast.com
May 10, 2002
Neoprobe Corp.
: 1Q02 Results, Operating Milestones Reached On Schedule
May 09, 2002
Neoprobe Corp.
: Recent Acquisition Holds Great Promise for NEOP, But Development Costs Will Reduce EPS through 2003
April 12, 2002
Neoprobe Corp.
: Neoprobe Sets Key Milestones for 2002 Performance; Investor Conference Call Set For Monday, March 11
March 08, 2002
Neoprobe Corp.
: Neoprobe Announces U.S. Regulatory Clearance for Biosonix Product
February 28, 2002
Neoprobe Corp.
: Neoprobe Announces Second Consecutive Year of Profitablility
February 25, 2002
Neoprobe Corp.
: Leach Technology Group and Neoprobe Corporation Sign Manufacturing Agreement
February 05, 2002
Neoprobe Corp.
: Neoprobe Completes License for Lymphatic Agent
February 04, 2002
Neoprobe Corp.
: Neoprobe Closes Biosonix Acquisition and Appoints Board Members
January 04, 2002
Neoprobe Corp.
: Neoprobe Announces Biosonix Acquisition
December 11, 2001
Neoprobe Corp.
: Neoprobe Secures $10 Million of Financing From Fusion Capital Fund and Engages Investor Relations Firm
November 29, 2001
Neoprobe Corp.
: 3Q01 Results Beat Forecast ñ Product Initiatives Pose Significant Potential
November 27, 2001
Neoprobe Corp.
: Neoprobe Announces First Blood Flow Product Receives European Market Registration
October 04, 2001
Neoprobe Corp.
: Biosonix Acquisition Will Provide Product Diversification and Other Synergies
September 10, 2001
Summary:New acquisition offers significant syneriges and long term potential.
Neoprobe Corp.
: Neoprobe to Acquire Bloodflow Technology Company
September 07, 2001
Neoprobe Corp.
: 2Q01 Results On Track to Post 2nd Year of Profitable Operations
August 29, 2001
Neoprobe Corp.
: Link to Interview of NEOPís CEO by Wall Street Reporter
June 28, 2001
Neoprobe Corp.
: Neoprobe eyeing acquisitions, new products
June 22, 2001
Neoprobe Corp.
: 1Q01 Margins Improve Despite Temporary Component Shortage
June 19, 2001
Neoprobe Corp.
: Aastrom Biosciences and Neoprobe Corporation Enter into Cell Therapy Development Agreement
June 11, 2001
Neoprobe Corp.
: CEO Interviewed on CEOcast.com
June 08, 2001
Neoprobe Corp.
: Operating Margins Improve Despite Temporary Component Shortage That Delayed Sales
May 10, 2001
Neoprobe Corp.
: Neoprobe Announces First Quarter Results
May 07, 2001
Neoprobe Corp.
: Marketing Alliance Results in First Profitable Year in Company History.
April 06, 2001
Summary: NEOP posted its first year of profitability due to the benefits of the marketing agreement with Ethicon Endo-Surgery, Inc. Their ILM product appears to be the standard in the field, but the regulatory approval process could slow the adoption rate. We lowered our earnings forecast to reflect a more conservative sales growth rate and increased R&D spending to widen their product line and keep abreast of technological advances. Despite our reduced expectations, our 12-18 month target price of $0.94 represents a potential gain of 88% from current levels.
Neoprobe Corp.
: Neoprobe Announces Record Operating Results
February 22, 2001
Neoprobe Corp.
: Neoprobe Collaborators Submit For Clinical Evaluation of Lymphatic Agent
February 14, 2001
Neoprobe Corp.
: Neoprobe Ranked #389 Fastest-Growing Technology Company in North America on Deloitte & Touche Technology Fast 500
November 16, 2000
Neoprobe Corp.
: NEOPís Marketing Alliance and Improved Operating Efficiencies Boost 3Q00 Sales 52% and EPS to $0.02 from a net loss of $0.15.
November 10, 2000
Neoprobe Corp.
: Neoprobe Announces Quarterly (3Q) Earnings and Record Year-to-Date Results
November 02, 2000
Neoprobe Corp.
: Neoprobe Poised to Benefit from Proprietary Cancer Detection Technology and Strategic Marketing Alliance
October 16, 2000
|
 |
|
|
|
Objective fundamental analysis and EPS forecasts on underfollowed small cap stocks.
